| ²é¿´: 683 | »Ø¸´: 1 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
Öò¹âÀïµÄ΢Цгæ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇóÖú£ºÖÐÎÄ·ÒëÓ¢ÎÄ
|
||
|
¢Ù¹Û²ì·ÇСϸ°û·Î°©¶ñÐÔÐØÇ»»ýÒºÓ¦Óö÷¶ÈÁªºÏ˳²¬ÐØÇ»ÄÚ×¢ÉäÖÎÁÆÊ±µÄÁÆÐ§ºÍ°²È«ÐÔ¡£ ¢Ú½«·ÇСϸ°û·Î°©ºÏ²¢¶ñÐÔÐØÇ»»ýÒºµÄ103Àý»¼ÕßËæ»ú·ÖΪÁ½×飬¶÷¶È+˳²¬£¨ÖÎÁÆ×飩ºÍ˳²¬£¨¶ÔÕÕ×飩£¬¸øÒ©ºóÆÀ¼ÛÒ©ÎïµÄÁÙ´²ÁÆÐ§¡¢»¼ÕßÉú»îÖÊÁ¿µÄ±ä»¯¼°²»Á¼·´Ó¦µÄ·¢ÉúÇé¿ö¡£ |
» ²ÂÄãϲ»¶
¡¾¿¼Ñе÷¼Á¡¿»¯Ñ§×¨Òµ 281·Ö£¬Ò»Ö¾Ô¸ËÄ´¨´óѧ£¬³ÏÐÄÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
ÄÜÔ´²ÄÁÏ»¯Ñ§¿ÎÌâ×éÕÐÊÕ˶ʿÑо¿Éú8-10Ãû
ÒѾÓÐ12È˻ظ´
288Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
0703»¯Ñ§µ÷¼Á
ÒѾÓÐ4È˻ظ´
ÕÐÊÕµ÷¼Á˶ʿ
ÒѾÓÐ10È˻ظ´
271²ÄÁϹ¤³ÌÇóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁÏר˶274Ò»Ö¾Ô¸ÉÂÎ÷ʦ·¶´óѧÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸Î人Àí¹¤²ÄÁϹ¤³Ìר˶µ÷¼Á
ÒѾÓÐ4È˻ظ´
085601²ÄÁϹ¤³Ìר˶Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
321Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
8814402
ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 509
- Ó¦Öú: 18 (СѧÉú)
- ¹ó±ö: 0.381
- ½ð±Ò: 12916.1
- É¢½ð: 47
- ºì»¨: 16
- Ìû×Ó: 4183
- ÔÚÏß: 357.8Сʱ
- ³æºÅ: 1184404
- ×¢²á: 2011-01-06
- רҵ: Ò©ÎïѧÆäËû¿ÆÑ§ÎÊÌâ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
Öò¹âÀïµÄ΢Ц: ½ð±Ò+10, ·ÒëEPI+1 2012-05-17 19:45:44
Öò¹âÀïµÄ΢Ц: ½ð±Ò+10, ·ÒëEPI+1 2012-05-17 19:45:44
|
To observe efficacy and safty of the combination of RH-endostatin and cisplatin by intralumen injection on non-small cell lung cancer with pleural effusion. 103 non-small cell lung cancer patients with malignant pleural effusion were randomly divided into two groups, treatment group (RH-endostatin and cisplatin) and control (cisplatin only), and the clinical efficacy, change of patients' life quality and adverse drug reactions following the intralumen injections were evaluated. |
2Â¥2012-05-17 08:41:05













»Ø¸´´ËÂ¥